恩必普联合脑蛋白水解物治疗血管性痴呆的临床研究

摘要

Objective To study the combination of Butylphthalide and Cerebroprotein Hydrolysate in treating vascular cognitive impairment. Methods 90 patients with vascular cognitive impairment were randomly divided into 2 groups, treatment group and control group. The treatment group of 45 cases was given Butylphthalide and Cerebroprotein Hydrolysate injection, the control group of 45 cases was only given Cerebroprotein Hydrolysate injection, with 1 month as a treatment course. The Mini-Mental State Examination(MMSE) and Activities of Daily Living(ADL) scores were used for evaluation of curative effect of the 2 groups of patients. Results After one month of treatment, The treatment group of Butylphthalide and Cerebroprotein Hydrolysate was superior to the control group of Cerebroprotein Hydrolysate injection in the the MMSE and ADL scores, there was statistical significance between 2 groups(P<0.05). Conclusion It is effective in treating vascular dementia of the combination of Butylphthalide and Cerebroprotein Hydrolysate injection, It is clear to improve patients cognitive function and the quality of life of the patients.%目的研究恩必普联合脑蛋白水解物注射液对血管性痴呆患者认知功能的作用。方法将90例血管性痴呆患者随机分为两组各45例，治疗组予以恩必普联合脑蛋白水解物注射液治疗，对照组用脑蛋白水解物注射液治疗。疗程1个月，治疗前后均采用简易智能状态量表(MMSE)和日常生活能力量表(ADL)评价临床疗效。结果治疗1月后，治疗组MMSE和ADL评分优于对照组，差异有统计学意义(P<0.05)。结论恩必普联合脑蛋白水解物注射液治疗血管性痴呆有效，能显著改善患者认知功能，提高生活质量。